Patents by Inventor Nobuo Cho
Nobuo Cho has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11986480Abstract: Provided is a novel compound or salt thereof that induces degradation by autophagy of an intracellular molecule. In this compound, a ligand having activity to bind to an intracellular molecule and a structure having activity to induce autophagy of an intracellular molecule are linked via a linker without loss of the activity of the ligand and the structure.Type: GrantFiled: February 2, 2018Date of Patent: May 21, 2024Assignee: TOHOKU UNIVERSITYInventors: Hirokazu Arimoto, Kaori Itto, Daiki Takahashi, Nobuo Cho, Hiroshi Nara, Kenichiro Shimokawa, Taiichi Ohra, Shigekazu Sasaki, Naoki Ishii
-
Publication number: 20230117295Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.Type: ApplicationFiled: December 6, 2022Publication date: April 20, 2023Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Koji ONO, Masahiro ITO, Toshio TANAKA, Moriteru ASANO, Takaharu HIRAYAMA, Jun FUJIMOTO, Nobuki SAKAUCHI, Yasuhiro HIRATA, Akinori TOITA, Nao MORISHITA, Hironori KOKUBO, Yasuhiro IMAEDA, Hironobu MAEZAKI, Douglas Robert CARY, Ryo MIZOJIRI, Nobuo CHO, Hiroshi BANNO, Hidekazu TOKUHARA, Yasuyoshi ARIKAWA
-
Patent number: 11584737Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.Type: GrantFiled: March 28, 2019Date of Patent: February 21, 2023Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Koji Ono, Masahiro Ito, Toshio Tanaka, Moriteru Asano, Takaharu Hirayama, Jun Fujimoto, Nobuki Sakauchi, Yasuhiro Hirata, Akinori Toita, Nao Morishita, Hironori Kokubo, Yasuhiro Imaeda, Hironobu Maezaki, Douglas Robert Cary, Ryo Mizojiri, Nobuo Cho, Hiroshi Banno, Hidekazu Tokuhara, Yasuyoshi Arikawa
-
Publication number: 20210363130Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.Type: ApplicationFiled: March 28, 2019Publication date: November 25, 2021Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Koji ONO, Masahiro ITO, Toshio TANAKA, Moriteru ASANO, Takaharu HIRAYAMA, Jun FUJIMOTO, Nobuki SAKAUCHI, Yasuhiro HIRATA, Akinori TOITA, Nao MORISHITA, Hironori KOKUBO, Yasuhiro IMAEDA, Hironobu MAEZAKI, Douglas Robert CARY, Ryo MIZOJIRI, Nobuo CHO, Hiroshi BANNO, Hidekazu TOKUHARA, Yasuyoshi ARIKAWA
-
Publication number: 20200163970Abstract: Provided is a novel compound or salt thereof that induces degradation by autophagy of an intracellular molecule. In this compound, a ligand having activity to bind to an intracellular molecule and a structure having activity to induce autophagy of an intracellular molecule are linked via a linker without loss of the activity of the ligand and the structure.Type: ApplicationFiled: February 2, 2018Publication date: May 28, 2020Inventors: Hirokazu ARIMOTO, Kaori ITTO, Daiki TAKAHASHI, Nobuo CHO, Hiroshi NARA, Kenichiro SHIMOKAWA, Taiichi OHRA, Shigekazu SASAKI, Naoki ISHII
-
Patent number: 9346822Abstract: The present invention provides a compound represented by the formula: wherein R1 is a C1-4 alkyl; R2 is (1) a 5- to 7-membered nitrogen-containing heterocyclic group which may have a substituent selected from the group consisting of (1?) a halogen, (2?) a hydroxy group, (3?) a C1-4 alkyl and (4?) a C1-4 alkoxy, (2) a phenyl which may have a substituent selected from the group consisting of (1?) a halogen, (2?) a C1-4 alkoxy-C1-4 alkyl, (3?) a mono-C1-4 alkyl-carbamoyl-C1-4 alkyl, (4?) a C1-4 alkoxy and (5?) a mono-C1-4 alkylcarbamoyl-C1-4 alkoxy, or the like; R3 is a C1-4 alkyl; R4 is a C1-4 alkoxy, or the like; n is an integer of 1 to 4; or a salt thereof, as a thienopyrimidine compound having gonadotropin-releasing hormone antagonistic activity.Type: GrantFiled: April 11, 2014Date of Patent: May 24, 2016Assignee: Takeda Pharmaceutical Company LimitedInventors: Nobuo Cho, Takashi Imada, Takenori Hitaka, Kazuhiro Miwa, Masami Kusaka, Nobuhiro Suzuki
-
Publication number: 20140221381Abstract: The present invention provides a compound represented by the formula: wherein R1 is a C1-4 alkyl; R2 is (1) a 5- to 7-membered nitrogen-containing heterocyclic group which may have a substituent selected from the group consisting of (1?) a halogen, (2?) a hydroxy group, (3?) a C1-4 alkyl and (4?) a C1-4 alkoxy, (2) a phenyl which may have a substituent selected from the group consisting of (1?) a halogen, (2?) a C1-4 alkoxy-C1-4 alkyl, (3?) a mono-C1-4 alkyl-carbamoyl-C1-4 alkyl, (4?) a C1-4 alkoxy and (5?) a mono-C1-4 alkylcarbamoyl-C1-4 alkoxy, or the like; R3 is a C1-4 alkyl; R4 is a C1-4 alkoxy, or the like; n is an integer of 1 to 4; or a salt thereof, as a thienopyrimidine compound having gonadotropin-releasing hormone antagonistic activity.Type: ApplicationFiled: April 11, 2014Publication date: August 7, 2014Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Nobuo CHO, Takashi IMADA, Takenori HITAKA, Kazuhiro MIWA, Masami KUSAKA, Nobuhiro SUZUKI
-
Patent number: 8735401Abstract: The present invention provides a compound represented by the formula: wherein R1 is a C1-4 alkyl; R2 is (1) a 5- to 7-membered nitrogen-containing heterocyclic group which may have a substituent selected from the group consisting of (1?) a halogen, (2?) a hydroxy group, (3?) a C1-4 alkyl and (4?) a C1-4 alkoxy, (2) a phenyl which may have a substituent selected from the group consisting of (1?) a halogen, (2?) a C1-4 alkoxy-C1-4 alkyl, (3?) a mono-C1-4 alkyl-carbamoyl-C1-4 alkyl, (4?) a C1-4 alkoxy and (5?) a mono-C1-4 alkylcarbamoyl-C1-4 alkoxy, or the like; R3 is a C1-4 alkyl; R4 is a C1-4 alkoxy, or the like; n is an integer of 1 to 4; or a salt thereof, as a thienopyrimidine compound having gonadotropin-releasing hormone antagonistic activity.Type: GrantFiled: September 23, 2011Date of Patent: May 27, 2014Assignee: Takeda Pharmaceutical Company LimitedInventors: Nobuo Cho, Takashi Imada, Takenori Hitaka, Kazuhiro Miwa, Masami Kusuka, Nobuhiro Suzuki
-
Patent number: 8338622Abstract: The present invention relates to a compound represented by wherein each symbol is as defined in the specification, a salt thereof and the like.Type: GrantFiled: May 29, 2009Date of Patent: December 25, 2012Assignee: Takeda Pharmaceutical Company LimitedInventors: Shizuo Kasai, Masahiro Kamaura, Nobuo Cho
-
Publication number: 20120071486Abstract: The present invention provides a compound represented by the formula: wherein R1 is a C1-4 alkyl; R2 is (1) a 5- to 7-membered nitrogen-containing heterocyclic group which may have a substituent selected from the group consisting of (1?) a halogen, (2?) a hydroxy group, (3?) a C1-4 alkyl and (4?) a C1-4 alkoxy, (2) a phenyl which may have a substituent selected from the group consisting of (1?) a halogen, (2?) a C1-4 alkoxy-C1-4 alkyl, (3?) a mono-C1-4 alkyl-carbamoyl-C1-4 alkyl, (4?) a C1-4 alkoxy and (5?) a mono-C1-4 alkylcarbamoyl-C1-4 alkoxy, or the like; R3 is a C1-4 alkyl; R4 is a C1-4 alkoxy, or the like; n is an integer of 1 to 4; or a salt thereof, as a thienopyrimidine compound having gonadotropin-releasing hormone antagonistic activity.Type: ApplicationFiled: September 23, 2011Publication date: March 22, 2012Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Nobuo Cho, Takashi Imada, Takenori Hitaka, Kazuhiro Miwa, Masami Kusaka, Nobuhiro Suzuki
-
Patent number: 8058280Abstract: The present invention provides a compound represented by the formula: wherein R1 is a C1-4 alkyl; R2 is (1) a 5- to 7-membered nitrogen-containing heterocyclic group which may have a substituent selected from the group consisting of (1?) a halogen, (2?) a hydroxy group, (3?) a C1-4 alkyl and (4?) a C1-4 alkoxy, (2) a phenyl which may have a substituent selected from the group consisting of (1?) a halogen, (2?) a C1-4 alkoxy-C1-4 alkyl, (3?) a mono-C1-4 alkyl-carbamoyl-C1-4 alkyl, (4?) a C1-4 alkoxy and (5?) a mono-C1-4 alkylcarbamoyl-C1-4 alkoxy, or the like; R3 is a C1-4 alkyl; R4 is a C1-4 alkoxy, or the like; n is an integer of 1 to 4; or a salt thereof, as a thienopyrimidine compound having gonadotropin-releasing hormone antagonistic activity.Type: GrantFiled: August 31, 2007Date of Patent: November 15, 2011Assignee: Takeda Pharmaceutical Company LimitedInventors: Nobuo Cho, Takashi Imada, Takenori Hitaka, Kazuhiro Miwa, Masami Kusaka, Nobuhiro Suzuki
-
Publication number: 20110251187Abstract: The present invention relates to a compound represented by wherein each symbol is as defined in the specification, a salt thereof and the like.Type: ApplicationFiled: May 29, 2009Publication date: October 13, 2011Inventors: Shizuo Kasai, Masahiro Kamaura, Nobuo Cho
-
Publication number: 20110009384Abstract: The present invention provides an agent for the prophylaxis or treatment of diabetes, which has a superior hypoglycemic action, and is associated with a fewer side effects such as body weight gain and the like. The resent invention relates an agent for the prophylaxis or treatment of diabetes, which comprises a compound represented by wherein each symbol is as defined in the description, or a salt thereof or a prodrug thereof.Type: ApplicationFiled: February 5, 2008Publication date: January 13, 2011Inventors: Taisuke Tawaraishi, Hiroshi Imoto, Nobuo Cho
-
Publication number: 20090264650Abstract: The present invention relates to a 11?-hydroxysteroid dehydrogenase 1 inhibitor comprising a compound represented by the formula (1): wherein each symbol is as defined in the description, or a salt thereof, or a prodrug thereof. The 11?-hydroxysteroid dehydrogenase 1 inhibitor of the present invention has a superior activity, and is useful as a pharmaceutical agent such as agents for the prophylaxis or treatment of diabetes, insulin resistance, obesity, abnormal lipid metabolism, hypertension and the like, and the like.Type: ApplicationFiled: March 31, 2006Publication date: October 22, 2009Inventors: Nobuo Cho, Shizuo Kasai, Toshiro Yamashita
-
Patent number: 7507753Abstract: The present invention provides a compound having melanocortin receptor agonist activity or antagonist activity, which is a novel biaryl compound represented by the formula (I): wherein ring A and ring B are optionally further substituted 6-membered aromatic rings; X is —CONR4—, —SO2NR4—, —CH2NR4— (R4 is a hydrogen atom, an optionally substituted hydrocarbon group, etc.), etc.; Y is a spacer having 1 to 12 atoms, etc.; Z is —CONR6—, —CO— (R6 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group), etc.; R1 is an optionally substituted amino group, etc.; R2 is an optionally substituted hydrocarbon group, etc.; R3 is an optionally substituted hydrocarbon group, etc.; and R5 is an optionally substituted hydrocarbon group, etc.; or a salt thereof.Type: GrantFiled: December 26, 2002Date of Patent: March 24, 2009Assignee: Takeda Chemical Industries Ltd.Inventors: Nobuo Cho, Kazuyoshi Aso, Satoshi Endo, Naoyuki Kanzaki, Satoshi Sasaki
-
Publication number: 20080194617Abstract: The present invention provides an agent for the prophylaxis or treatment of diabetes, which has a superior hypoglycemic action, and is associated with a fewer side effects such as body weight gain and the like. The present invention relates an agent for the prophylaxis or treatment of diabetes, which comprises a compound represented by wherein each symbol is as defined in the description, or a salt thereof or a prodrug thereof.Type: ApplicationFiled: February 6, 2008Publication date: August 14, 2008Inventors: Taisuke Tawaraishi, Hiroshi Imoto, Nobuo Cho
-
Publication number: 20080108623Abstract: The present invention provides a compound represented by the formula: wherein R1 is a C1-4 alkyl; R2 is (1) a 5- to 7-membered nitrogen-containing heterocyclic group which may have a substituent selected from the group consisting of (1?) a halogen, (2?) a hydroxy group, (3?) a C1-4 alkyl and (4?) a C1-4 alkoxy, (2) a phenyl which may have a substituent selected from the group consisting of (1?) a halogen, (2?) a C1-4 alkoxy-C1-4 alkyl, (3?) a mono-C1-4 alkyl-carbamoyl-C1-4 alkyl, (4?) a C1-4 alkoxy and (5?) a mono-C1-4 alkylcarbamoyl-C1-4 alkoxy, or the like; R3 is a C1-4 alkyl; R4 is a C1-4 alkoxy, or the like; n is an integer of 1 to 4; or a salt thereof, as a thienopyrimidine compound having gonadotropin-releasing hormone antagonistic activity.Type: ApplicationFiled: August 31, 2007Publication date: May 8, 2008Applicant: Takeda Pharmaceutical Company LimitedInventors: Nobuo Cho, Takashi Imada, Takenori Hitaka, Kazuhiro Miwa, Masami Kusaka, Nobuhiro Suzuki
-
Patent number: 7300935Abstract: The present invention provides a compound represented by the formula: wherein R1 is a C1-4alkyl; R2 is (1) a 5- to 7-membered nitrogen-containing heterocyclic group which may have a substituent selected from the group consisting of (1?) a halogen, (2?) a hydroxy group, (3?) a C1-4alkyl and (4?) a C1-4alkoxy, (2) a phenyl which may have a substituent selected from the group consisting of (1?) a halogen, (2?) a C1-4alkoxy-C1-4alkyl, (3?) a mono-C1-4alkyl-carbamoyl-C1-4alkyl, (4?) a C1-4alkoxy and (5?) a mono-C1-4alkylcarbamoyl-C1-4alkoxy, or the like; R3 is a C1-4alkyl; R4 is a C1-4alkoxy, or the like; n is an integer of 1 to 4; or a salt thereof, as a thienopyrimidine compound having gonadotropin-releasing hormone antagonistic activity.Type: GrantFiled: January 28, 2004Date of Patent: November 27, 2007Assignee: Takeda Pharmaceutical CompanyInventors: Nobuo Cho, Takashi Imada, Takenori Hitaka, Kazuhiro Miwa, Masami Kusaka, Nobuhiro Suzuki
-
Publication number: 20060160829Abstract: The present invention provides a compound represented by the formula: wherein R1 is a C1-4 alkyl; R2 is (1) a 5- to 7-membered nitrogen-containing heterocyclic group which may have a substituent selected from the group consisting of (1?) a halogen, (2?) a hydroxy group, (3?) a C1-4 alkyl and (4?) a C1-4 alkoxy, (2) a phenyl which may have a substituent selected from the group consisting of (1?) a halogen, (2?) a C1-4 alkoxy-C1-4 alkyl, (3?) a mono-C1-4 alkyl-carbamoyl-C1-4 alkyl, (4?) a C1-4 alkoxy and (5?) a mono-C1-4 alkylcarbamoyl-C1-4 alkoxy, or the like; R3 is a C1-4 alkyl; R4 is a C1-4 alkoxy, or the like; n is an integer of 1 to 4; or a salt thereof, as a thienopyrimidine compound having gonadotropin-releasing hormone antagonistic activity.Type: ApplicationFiled: January 28, 2004Publication date: July 20, 2006Inventors: Nobuo Cho, Takashi Imada, Takenori Hitaka, Kazuhiro Miwa, Masami Kusaka, Nobuhiro Suzuki
-
Publication number: 20050096359Abstract: The present invention provides a compound having melanocortin receptor agonist activity or antagonist activity, which is a novel biaryl compound represented by the formula (I): wherein ring A and ring B are optionally further substituted 6-membered aromatic rings; X is —CONR4—, —SO2NR4—, —CH2NR4— (R4 is a hydrogen atom, an optionally substituted hydrocarbon group, etc.), etc.; Y is a spacer having 1 to 12 atoms, etc.; Z is —CONR6—, —CO— (R6 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group), etc.; R1 is an optionally substituted amino group, etc.; R2 is an optionally substituted hydrocarbon group, etc.; R3 is an optionally substituted hydrocarbon group, etc.; and R5 is an optionally substituted hydrocarbon group, etc.; or a salt thereof.Type: ApplicationFiled: December 26, 2002Publication date: May 5, 2005Inventors: Nobuo Cho, Kazuyoshi Aso, Satoshi Endo, Naoyuki Kanzaki, Satoshi Sasaki